Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 9/20 | 0.49 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116564 | 0.89 | ACVRL1 (0.51) | TYRO3ACVRL1AXL | |
| SCHEMBL57887 | 0.81 | TYRO3 (0.52) | TYRO3ACVRL1AXLMERTK | |
| SCHEMBL5146643 | 0.79 | ACVRL1 (0.53) | TYRO3ACVRL1PIK3CD | |
| SCHEMBL59086 | 0.79 | TYRO3 (0.47) | TYRO3ACVRL1AXLMERTK | |
| SCHEMBL3005217 | 0.78 | ACVRL1 (0.57) | ACVRL1PIK3CDMERTK | |
| SCHEMBL5130595 | 0.78 | ACVRL1 (0.45) | ACVRL1PIK3CDMERTK | |
| SCHEMBL59657 | 0.76 | RET (0.52) | TYRO3ACVRL1AXLMERTK | |
| SCHEMBL27747228 | 0.76 | BTK (0.46) | TYRO3ACVRL1AXLMERTK | |
| SCHEMBL58840 | 0.76 | TYRO3 (0.52) | TYRO3ACVRL1AXLMERTK | |
| SCHEMBL58943 | 0.74 | BTK (0.45) | TYRO3ACVRL1AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | TYRO3 2455/4885ACVRL1 941/4885PIK3CD 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.